Department of Health and Human Services


Part 1. Overview Information
Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Human Genome Research Institute (NHGRI)

This is an NIH-wide initiative that is being administered by NHGRI on behalf of NIH.

Funding Opportunity Title

Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01)

Activity Code

X01 Resource Access Award

Announcement Type

Reissue of PAR-11-210

Related Notices
  • June 4, 2014 - Notice NOT-14-074 supersedes instructions in Section III.3 regarding applications that are essentially the same.
  • May 23, 2014 - Notice of Clarification and Correction to PAR-14-207. See Notice NOT-HG-14-028.
Funding Opportunity Announcement (FOA) Number

PAR-14-207

Companion Funding Opportunity

None  

Number of Applications

See Section III. 3. Additional Information on Eligibility.

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.172

Funding Opportunity Purpose

The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease.  The laboratory specializes in genomic services that can't be readily handled by individual investigator laboratories. CIDR provides the most up-to-date platforms, services and statistical genetic support. This is an NIH-wide initiative that is managed by NHGRI.  Information about the current services offered can be accessed via: http://www.cidr.jhmi.edu.

Key Dates
Posted Date
Open Date (Earliest Submission Date)

Now May 28, 2014 per NOT-HG-14-028 (Originally July 1, 2014)

Letter of Intent Due Date(s)

Not Applicable

Application Due Date(s)

Applications are accepted by continuous receipt, per NOT-HG-13-008

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

We expect to review application six times a year, with one meeting in each of the following windows: September 2014; November 2014; January 2015; March 2015, April-May 2015; July 2015; September 2015; November 2015;  January 2016; March 2016; April-May 2016; July 2016; September 2016; November  2016;  January 2017;  March 2017; April-May 2017; July 2017

Advisory Council Review

Not Applicable

Earliest Start Date

October 15, 2014; December 15, 2014; February 15, 2015; April 15, 2015, June 15, 2015;  August 15, 2015;  October 15, 2015;  December 15, 2015;   February 15, 2016;  April 15, 2016;  June 15, 2016;  August 15, 2016;  October 15,  2016; December 15, 2016;  February 15, 2017;  April 15, 2017; June 15, 2017; - August 15, 2017

Expiration Date

July 2, 2017

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.


A compatible version of Adobe Reader is required for download. For Assistance downloading this or any Grants.gov application package, please contact Grants.gov Customer Support at http://www.grants.gov/contactus/contactus.jsp.
Table of Contents

Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information

Part 2. Full Text of Announcement


Section I. Funding Opportunity Description


Purpose

With continued advances in our ability to identify human genetic variation, there is great interest in applying state-of the art technology to find genetic elements important in human health and disease.  For many studies, this requires high-throughput technologies that cannot be efficiently carried out in individual investigator laboratories. 

This FOA allows investigators to apply for access to high-throughput sequencing and genotyping services carried out by CIDR.  The services provided include careful quality control and data cleaning.  Some statistical analysis service is also offered.  Detailed information about current CIDR offerings can be found at http://www.cidr.jhmi.edu.

Specific Areas of Research Interest

The FOA seeks projects that show promise of identifying genetic or epigenetic elements important to human health and disease.  There should be strong evidence that the project proposed will have sufficient power to detect genetic or epigenetic factors affecting the trait under study.   Appropriate projects would include but not be limited to: whole-genome, whole exome and custom-targeted next-generation sequencing; human genome wide association studies (GWAS), high-throughput custom SNP genotyping and analyses of DNA methylation.  Although the main focus of this FOA is on human studies, some model organism studies are also appropriate.

Section II. Award Information
Funding Instrument

Other:  A mechanism that is not a grant or cooperative agreement. Examples include access to research resources or pre-applications.

Application Types Allowed

New
Resubmission

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

Funds Available and Anticipated Number of Awards

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award Budget

Not Applicable; there is no budget associated with X01 Resource Access Awards.

Award Project Period

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Section III. Eligibility Information


1. Eligible Applicants


Eligible Organizations

Higher Education Institutions

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

Nonprofits Other Than Institutions of Higher Education

For-Profit Organizations

Governments

Other

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are  eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are  eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are  allowed.

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility


Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission:

Section IV. Application and Submission Information


1. Requesting an Application Package

Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed, with the following exceptions or additional requirements:

Required and Optional Components

The forms package associated with this FOA includes all applicable components, required and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate “optional” components.

Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

Total Federal Funds Requested:  Enter $0.

Total Federal & Non-Federal Funds:  $0.

Estimated Program Income:  Enter $0.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed. 

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.  

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Specific Aims: The Specific Aims should refer directly to the X01 request.

Research Strategy:

Significance:

1) Explain the public health significance of the trait under study. 

2) Document the evidence for a genetic component of this trait and the likely strength of that component, including the heritability and complexity. 

3) Describe earlier genetic studies on this disorder, and what has been found so far. 

4) Describe known environmental risk factors for this trait, and the evidence for their involvement. Also discuss any evidence for gene-environment interactions.

5) If this request is a direct follow up of an earlier study, describe those results.

6) Provide any additional background that supports the value of the high-throughput service(s) requested.

Innovation and Approach:

1) Study Population:  Clearly describe the study population. Include detailed information about how subjects were identified and sampled and the method(s) of phenotypic characterization. For case-control studies, provide inclusion and exclusion criteria and any matching done between cases and controls. Describe relevant environmental factors and how they were measured.  If the subjects provided for this study are a subset of a family population, explain which individuals were included and how they were selected.   Highlight special features of the study population that would enhance success.

2) Sample Information and Service(s) Requested:  In table form, provide: sample description such as case/control status and/or collection site; number of samples included in the study;   tissue source of the DNA; service requested; and previous genotyping or sequencing.   If data from other subjects will be included in the analysis, add row(s) to describe those samples. 

Sample Set

(include reference name, case/control status and/or collection site if relevant)

Number of Samples

DNA Source

Service Requested

Previous Genotyping or Sequencing

ABC probands

3000

blood

5Mb custom -targeted sequencing

Illumina OmniExpress

ABC controls

3000

blood

5Mb custom-targeted sequence

Illumina Omni Express


Provide supporting text that justifies the choice of samples.  Describe the extraction methods used for each DNA source and the approximate DNA concentrations.  Describe previous genotyping or sequencing done on these subjects.  (See: http://www.cidr.jhmi.edu for sample requirements.)

3) Power and Effect Size: Use power analyses to describe the range of effect sizes detectable by the study.  Address relevant features of the analytic plan, such as the genetic model(s) to be tested, the extent of multiple testing and what significance level would be used for testing.  If appropriate, include parameters such as risk allele frequencies and the expected patterns of linkage disequilibrium. If the study design requires separate analysis of subject groups (e.g. phenotypic classes or ancestry groups) provide power analyses for each category.  If there is a plan to test for gene-gene or gene -environment effects, address the power for detection of these effects.

For sequencing studies, provide power calculations that include correction for the number of markers estimated.  If there is a plan to sequence a discovery set and then validate via genotyping or custom sequencing provide power for the validation set.

4) Data Analyses:  Provide a thorough plan for data analyses. Include: analytical approaches to be used and their justification; plans for quality control analyses; methods to control for possible confounding effects such as genotype and/or phenotype uncertainty; how false positive rates will be controlled in light of multiple testing etc.  If relevant, also discuss how the trait or locus will be localized.   For sequencing studies, include methods for variant filtering and follow up.  If there is a plan to analyze the data obtained with earlier data, describe your strategy for that process.   For sequencing requests, also explain plans for filtering the SNPS detected. 

Describe the role of each team member in the analysis process, and summarize the team's experience with the approaches proposed.

5) Data Management:  Describe the institutional computing resources available for this study, the type of data base that will be used, and how the data will be managed.  Highlight the team's experience with management of large data sets (especially those similar to the proposed project).  Also describe strategies to maintain data security.

6) Plans for the Next Phase:  Describe plans for follow-up studies. For example, additional genotyping or sequencing and/or functional testing of selected variants. 

Letters of Support:  If collaborations have been established for follow up, included letters of collaboration in the applicationthat document the role of each collaborator. Letters should be combined into a single PDF and uploaded via the Letters of Support attachment.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guidewith the following addition: All CIDR applications should provide a detailed description of the data and resource sharing plan. A data dictionary of the phenotypic measures to be shared and a summary of the number of subjects who have data for those measures should be attached to the application. A sample data dictionary and data summary can be found at: http:// www.cidr.jhmi.edu.

Appendix:  Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

Foreign Institutions

Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

3. Submission Dates and Times

Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

4. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

5. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Not Applicable. No funds are involved with this Resource Access Award.

6. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.

Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.

In order to expedite review, applicants are requested to notify the NHGRI Referral Office by email at dayc@mail.nih.go} when the application has been submitted. Please include the FOA number and title, PD/PI name, and title of the application.

Letters of Permission to Submit an Application

It is expected that access to CIDR resources will be linked to a present or future research grant from a participating NIH Institute. All applications must obtain permission from a CIDR supporting NIH Institute to submit an application in response to this FOA. A list of participating Institutes and contacts for CIDR submission can be found at: http://www.cidr.jhmi.edu/NIH%20Institute%20CIDR%20Program%20Liaisons_sent.pdf.   It is recommended that you discuss your application with the staff from one of the CIDR supporting NIH Institutes four to six months in advance of the planned submission.  A letter documenting the permission should be included in the application.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.

Section V. Application Review Information


1. Criteria

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

The X01 Resource Access Program invites eligible institutions to seek access to NIH research resources, which are specified in each X01 FOA.  This includes programs where institutions will request access to submit to the resource (e.g., high throughput screening assays) as well as programs where access to a specific NIH research resource is needed to conduct certain research.  Important factors in the peer review of X01 applications are the need for, and potential benefit of, gaining access to the resource, specifications for any assays proposed, timelines for completion and plans for follow-on studies.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

SignificanceIs the trait under study important to human health?  Is there strong evidence for a genetic component and documentation of the anticipated size of the genetic effect? Does current knowledge about the genetic landscape of this trait support the need for the high-throughput service requested?  Will the study identify genes or genetic variants important to human disease and/or provide new biological or technical insights?

Investigator(s)     

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Is the expertise in place for each aspect of the project, including the data management and analysis? Is there evidence that the investigators listed will be able to expend the needed effort?  

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?   

Approach

Are the overall strategy, methodology and analyses well-reasoned and appropriate to accomplish the specific aims of the study?  Is the study design well chosen? Are the genetic services requested the most appropriate for the question addressed? Are the phenotypic and environmental measures appropriately chosen and carefully determined?  Are there appropriate plans for both data analysis and data management?   Is the sample size sufficient to detect the likely genetic effect(s)? Are validation plans in place? Are potential problems considered and alternative strategies presented? Are there adequate plans for follow-up to identify specific genes or genetic variant(s) affecting the trait under study?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?      

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items. 

Protections for Human Subjects

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Children 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

Renewals

Not Applicable

Revisions

Not Applicable

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NHGRI Scientific Review Branch .. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information


1. Award Notices

Any application awarded in response to this FOA will be subject to the DUNS, SAM Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General  and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Cooperative Agreement Terms and Conditions of Award

Not Applicable

3. Reporting

When multiple years are involved, awardees will be required to submit the annual Non-Competing Progress Report (PHS 2590 or RPPR) and financial statements as required in the NIH Grants Policy Statement.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Commons Help Desk (Questions regarding eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

Finding Help Online: http://grants.nih.gov/support/index.html

TTY: 301-451-5939
Email: commons@od.nih.gov

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact CenterTelephone: 800-518-4726

Web ticketing system: https://grants-portal.psc.gov/ContactUs.aspx
Email: support@grants.gov

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Telephone: 301-435-0714
TTY 301-451-5936
Email: GrantsInfo@nih.gov

Scientific/Research Contact(s)

Camilla Day, PhD
National Human Genome Research Institute (NHGRI)
Telephone: 301-402-8837
Email: dayc@mail.nih.gov

Peer Review Contact(s)

Camilla Day, PhD
National Human Genome Research Institute (NHGRI)
Telephone: 301-402-8837
Email: dayc@mail.nih.gov

Financial/Grants Management Contact(s)

Not Applicable

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices



NIH Office of Extramural Research Logo
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®



Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.